ASPIRIN AND DIPYRIDAMOLE

Post-LOE

aspirin; dipyridamole

Fosun Pharma
ANDAORALCAPSULE, EXTENDED RELEASE
Approved
Aug 2018
Lifecycle
Post-LOE
Competitive Pressure
30/100

Mechanism of Action

extended-release dipyridamole is the result of the additive antiplatelet effects of dipyridamole and aspirin. Dipyridamole Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes in vitro and in vivo ; the inhibition occurs in a dose-dependent manner at…

Indications (2)

stroke in patientscompleted ischemic stroke due to thrombosis
Company
FP
Fosun Pharma
Australia - Sydney
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers
Data Sources
  • Drug label: DailyMed / FDA
  • Clinical trials: ClinicalTrials.gov
  • Patent data: FDA Orange Book
  • Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.